Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
Year: 2006
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Authors: W. Pönisch, P. S. Mitrou, K. Merkle, M. Herold, M. Assmann, G. Wilhelm, K. Dachselt, P. Richter, V. Schirmer, A. Schulze, R. Šubert, B. Harksel, N. Grobe, E. Stelzer, M. Schulze, A. Bittrich, M. Freund, R. Pasold, Th. Friedrich, W. Helbig, D. Niederwieser
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2074533771
